

Study links hs-cTnT to MACE, mortality in rheumatoid arthritis

June 27 2024, by Elana Gotkine



For patients with rheumatoid arthritis (RA), a detectable level of high-sensitivity cardiac troponin T (hs-cTnT) is associated with increased risk of major adverse cardiovascular events (MACE) and all-cause mortality,

according to a research letter [published](#) online June 15 in the *Journal of Rheumatology*.

Brittany N. Weber, M.D., Ph.D., from Brigham and Women's Hospital in Boston, and colleagues examined the longer-term association between clinically established thresholds for detectable hs-cTnT with MACE ([acute coronary syndrome](#), stroke, and [cardiovascular death](#)) and all-cause mortality among 331 patients with RA.

The median calculated 10-year atherosclerotic cardiovascular disease (ASCVD) risk was 3.87%. The researchers found that 117 patients (35.3%) had detectable hs-cTnT (median level, 8.98 mg/dL). In 10 years, 16 MACE occurred (4.8%), with 50 all-cause deaths (15.1%).

There was an association seen for detectable hs-cTnT with future MACE (hazard ratio [HR], 7.13); the significant association persisted after adjustment for ASCVD risk and log high-sensitivity C-reactive protein (hsCRP; HR, 4.29) and for baseline ASCVD risk and Disease Activity Score in 28 joints based on CRP (DAS28-CRP). Corresponding associations were seen for detectable hs-cTnT and all-cause mortality (HR, 7.2), which also persisted after adjustment (HRs, 4.18 and 4.74, respectively). ASCVD risk score alone was significantly associated with MACE.

"These findings suggest that hs-cTnT may be a useful marker to improve cardiovascular risk assessment among patients with RA with overall low estimated ASCVD risk," the authors write.

Several authors disclosed ties to the [pharmaceutical industry](#).

More information: Brittany N. Weber et al, The Association Between High-Sensitivity Cardiac Troponin T and Major Adverse Cardiovascular Events in Rheumatoid Arthritis, *The Journal of Rheumatology* (2024).

[DOI: 10.3899/jrheum.2024-0168](https://doi.org/10.3899/jrheum.2024-0168)

© 2024 [HealthDay](#). All rights reserved.

Citation: Study links hs-cTnT to MACE, mortality in rheumatoid arthritis (2024, June 27)
retrieved 8 August 2024 from
<https://medicalxpress.com/news/2024-06-links-hs-ctnt-mace-mortality.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.